Introduction
The neuropathology of Alzheimer's disease (AD) is characterized by extensive neuronal loss and the presence of two different types of fibrillar deposits, amyloid plaques and neurofibrillary tangles (reviewed in Yankner and Mesulam, 1991) . Mature amyloid plaques are composed of a core of ~-amyloid (13A) surrounded by dystrophic neurites and an infiltrate of reactive astrocytes and microglia. Neurofibrillary tangles are intracellular bundles of straight or paired helical filaments that form in the cytoplasm of degenerating neurons. Considerable evidence suggests that the major constituent of paired helical filaments (PHFs) is hyperphosphorylated tau that self-associates via its microtubule-binding domain (Grundke-lqbal et al., 1986; Kosik et al., 1986; Wood et al., 1986; Greenberg and Davies, 1990; Ksiezak-Reding and Yen, 1991; Lee et al., 1991) .
The cause of aberrant tau phosphorylation leading to PHF formation in the AD brain is unknown.
The 13A in amyloid plaques is derived by proteolytic cleavage of the amyloid precursor protein (APP; Kang et al., 1987) . Soluble 13A is produced during the normal metabolism of APP by a variety of cell types in culture and is present in cerebrospinal fluid and plasma (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992; Busciglio et al., 1993a) . Several lines of evidence suggest that I~A accumulation is a central event in the pathophysiology of AD. First, genetic studies of families with autosomal dominant inheritance of AD have demonstrated several mutations in APP which flank the proteolytic cleavage sites that give rise to 13A (reviewed by Haass and Selkoe, 1993) . One inherited mutation associated with familial AD in Sweden increases 13A production by severalfold (Citron et al., 1992; Cai et al., 1993) . Another inherited mutation at APP codon 717 increases production of the longer and more amyloidogenic 42 amino acid form of J3A (Suzuki et al., 1994) . A second line of evidence is the high propensity of individuals with Down's syndrome to develop AD by middle age, presumably owing to the overexpression of APP associated with trisomy 21. Third, the fibrillar form of 13A present in neuritic plaques in the AD brain is neurotoxic .
Following the initial observation that 13A is neurotoxic (Yankner et al., 1990) , several studies showed a strong correlation between ~A neurotoxicity and the aggregation state of the peptide (Pike et al., 1991; Busciglio et al., 1992; Mattson et al., 1993) . We have recently demonstrated that aggregation by itself is not sufficient, but rather that fibril formation is required for neurotoxicity . The neurotoxicity of fibrillar [3A is associated with dramatic morphological alterations in rat and human neurons, including neuronal shrinkage and severe axonal and dendritic dystrophy (Yankner et al., 1990; Pike et al., 1992; Busciglio et al., 1993b) . Similar dystrophic changes in neuritic morphology occur in the AD brain in neurons that develop neurofibrillary pathology. A key biochemical event underlying this phenomenom is the hyperphosphorylation of tau (for review, see Lee and Trojanowski, 1992; Goedert, 1993; Mandelkow and Mandelkow, 1993) .
A central issue in the pathogenesis of AD is the relationship between amyloid plaque formation and the development of neurofibrillary changes in the neuronal cytoskeleton. To determine whether 13A can alter the phosphorylation state of tau, we examined primary cultures of rat and human neurons exposed to fibrillar and nonfibrillar ~A using monoclonal antibodies that distinguish phosphorylation-dependent epitopes present in PHFs. Fibrillar 13A induced a dramatic increase in tau phosphorylation. The 13A-induced phosphorylated tau resembled PHF-associated tau in its localization to the neuronal somatodendritic compartment and inability to bind to microtubules. Primary rat hippocampal cultures were treated for 4 days with vehicle or 20 p.M fibrillar ~A, and immunofluorescence staining was performed with the rnonoclonal antibodies PHF-1 (A-D) and AP20 (to MAP2; E). PHF-1 irnmunoreactivity in control cultures is confined to axons (A and C). Note that treatment with fibrillar ~A markedly increases PHF-1 irnrnunoreactivity (B) and results in accumulation of the PHF-1 antigen in the sornatodendritic compartment, as determined by double labeling with PHF-1 (D) and anti-MAP2 (E). Bars, 40 ~rn (A and B), 10 ~.m (C-E).
Results

Fibrillar pA Induces Tau Phosphorylation at PHF-Associated Epitopes
To determine whether ~A can produce some of the biochemical features of neurofibrillary degeneration, we analyzed the microtubule-associated protein tau in primary rat hippocampal cultures treated with I~A fibrils, which have been shown to mediate I~A neurotoxicity . Rat hippocampal cultures enriched in pyramidal neurons were maintained at high cell density for 5 days in culture to permit neuronal differentiation and were then treated with vehicle, soluble I3A, or fibrillar ~A for 4 days. Immunocytochemical analysis was performed with the PHF-1 monoclonal antibody, which specifically recognizes a tau epitope phosphorylated at Ser-396/Ser-404 in PHFs (Greenberg et al., 1992; Lang et al., 1992) . These tau epitopes are also phosphorylated in normal fetal brain neurons Watanabe et al., 1993) . In cultured rat hippocampal neurons, PHF-1 immunoreactMty was detected predominantly in distal axons. The neuronal soma and dendrites were not labeled (Figures 1A and 1C) . Treatment with soluble I~A showed the same pattern of PHF-1 labeling (data not shown). In contrast, treatment with ~A fibrils resulted in a marked induction and altered localization of PHF-1 immunoreactivity ( Figure 1B) . PHF-1 immunoreactivity in neurons exposed to ~A fibrils was no longer confined to axons, but now also appeared in the somatodendritic compartment, as determined by double labeling with an antibody to microtubule-associated protein 2 (MAP2; Figures 1D and 1E ). Immunocytochemistryoffibrillar~A-treated neuronswith the monoclonal antibody AT8, which is specific for a different phosphorylation-dependent epitope, also demonstrated tau induction in the somatodendritic compartment (data not shown).
To determine whether the induction of tau phosphorylation is specifically mediated by the 13A fibril, we compared the effects of fibrillar and amorphous-aggregated 13A. For these experiments, the 1-42 13A peptide was used because it can form amorphous aggregates that are stable in cell culture . Amorphousaggregated 13A did not induce PHF-1 immunoreactivity in rat hippocampal cultures, in contrast to 15A fibrils, which caused a robust induction (Figure 2 ). These results indicate that I~A fibril formation is required for the induction of the PHF-1 antigen.
To confirm that the increased PHF-1 immunoreactivity induced by ~A fibrils is due to increased tau phosphorylation, the cultures were fixed, permeabilized, and treated with alkaline phosphatase in the presence of protease inhibitors prior to imrnunocytochemistry with PHF-I. Dephosphorylation with alkaline phosphatase completely abolished immunoreactivity with PHF-1 ( Figures 3A and  3B ). In contrast, dephosphorylation increased neuronal immunoreactivity with the Tau-1 monoclonal antibody, which specifically recognizes the Ser-202 epitope in the nonphosphorylated state ( Figures 3C and 3D ) (Binder et al., 1985; Lee et al., 1991; Biernat et al., 1992) , consistent with the exposure of a tau epitope previously masked by phosphorylation. The levels of phosphorylated and nonphosphorylated tau were further examined by Western blot analysis of neuronal cell lysates. In rat hippocampal neurons, a single PHF-l-immunoreactive band at 55 kDa was detected that was markedly induced by fibriliar ~A (7.4 _+ 0.4-fold increase, mean _+ SEM; n = 3; p < .01), but was unaffected by soluble I3A ( Figure 4A ). Fibrillar ~A also markedly induced phosphorylation of tau at an epi- Figure  1A . Bar, 40 I~m. tope recognized by the AT8 monoclonal antibody ( Figure  4A ), which is specific for phosphorylation at Ser-202 (Biernat et al., 1992; Goedert et al., 1993) . In contrast, fibrillar ~A did not significantly alter the level of tau detected by the Tau-1 antibody (81% _+ 4% of control), which recognizes the Ser-202 epitope in the nonphosphorylated state. In addition, the levels of MAP2 and tubulin were not significantly altered relative to total cellular protein after treatment with fibrillar I~A ( Figure 4A ). These results suggest that fibrillar I3A increases the absolute and relative levels of tau phosphorylated at epitopes associated with PHFs. Fibrillar 13A causes progressive neuronal degeneration in high density cultures of rat hippocampal neurons resulting in an approximately 500/0 loss of neuronal viability after 3-4 days ( Table 1) . To determine whether induction of tau phosphorylation is secondary to neuronal degeneration, neurons treated with 13A fibrils were double labeled with the vital dye propidium iodide and with PHF-I. Propidium is selectively taken up into the nuclei of nonviable cells due to loss of membrane integrity. Fibrillar ~A induced tau phosphorylation in neurons that were morphologically intact and were not labeled by propidium, indicating that they were viable ( Figure 5 ). Quantitation of neuronal viability showed that fibrillar I3A induced the appearance of PHF-l-immunoreactive tau in the somatodendritic compartment prior to significant neuronal degeneration and cell death (Table 1) . After longer time intervals in culture, PHF-l-positive neurons with a degenerative morphology were clearly evident. Thus, induction of tau phosphorylation and somatodendritic accumulation are an early neuronal response to fibrillar 13A that precedes neuronal degeneration.
Fibrillar pA Induces Tau Phosphorylation and an Electrophoretic Mobility Shift in Human Cortical Neurons
To determine whether fibrillar 13A also affects tau phosphorylation in human cortical neurons, we examined pri- [}, .~ Figure 3 . Phosphatase Sensitivity of the 13A-Induced PHF-1 Antigen (A and B) P H F-1 antibody; (C and D)Tau-1 antibody. Rat hippocampal neurons treated with fibrillar p,A were fixed, permeabilized, and stained with the PHF-1 or Tau-1 antibody before (A and C) and after (B and D) alkaline phosphatase treatment (as described in Experimental Procedures). Note that dephosphorylation abolishes staining with PHF-1 and increases somatodendritic staining with Tau-l. Bar, 40 pro. mary cultures of fetal human cortical neurons from 17 week-gestation abortuses. We have previously demonstrated that aggregated ~A is toxic to human cortical neurons in culture (Busciglio et al., 1992 (Busciglio et al., , 1993b . Phosphorylated tau is normally present in the distal axons of human cortical neurons, as observed for rat hippocampal neurons ( Figure 1A ; Figure 6A ). Fibrillar I3A caused a dramatic induction of PHF-1 immunoreactivity in human cortical neurons, with accumulation in the somatodendritic compartment, whereas soluble 13A had no significant effect ( Figures 6A and 6B ). Western blot analysis with the PHF-1 antibody showed a major 55 kDa band and a minor 58 kDa band in control human cortical cultures and cultures treated with soluble 13A. Fibrillar ~A caused a dramatic induction of PHF-1-immunoreactive tau, with a shift in Mr of the predominant tau bands from 55 kDa to 56-59 kDa ( Figure 6C ). Dephosphorylation completely abolished PHF-1 immunoreactivity, confirming that the epitope is phosphorylated. Western blot analysis of human cortical neurons with the Tau-1 antibody showed that fibrillar I3A did not significantly affect the level of the nonphosphorylated Ser-202 tau epitope in human cortical cultures ( Figure 6C ). However, alkaline phosphatase treatment of the blot revealed an additional higher Mr band that was detected by the Tau-1 antibody only in cells treated with fibrillar [3A ( Figure 6C ), providing further evidence that 13A-induced tau phosphorylation shifts the tau Mr. The higher Mr forms of tau were recognized to a lesser extent by Tau-1 in dephosphorylated blots than by PHF-1 in untreated blots, possibly owing to higher levels of phosphorylation of the PHF-1 epitope than of the Tau-1 epitope. Thus, in human cortical neurons fibrillar 13A-induced tau phosphorylation results in a shift in Mr, reminiscent of the Mr shift exhibited by phosphorylated tau in the AD brain.
pA-Induced Tau Phosphorylation Inhibits Microtubule Binding
Recent reports suggest that PHF-tau in the AD brain has lost the capacity to bind to microtubules Biernat et al., 1993; Alonso et al., 1994) . To determine whether ~A-induced tau is bound to microtubules, untreated and fibrillar 13A-treated neurons were extracted with Triton X-100 under microtubule-stabilizing conditions. toskeleton. In contrast, detergent extraction completely released the 13A-induced tau from the neuronal somatodendritic compartment (Figure 7) . In neurons treated with fibrillar 15A, axonal PHF-l-immunoreactive tau remained after detergent extraction (Figure 7 , arrows), suggesting that a component of normal fetal tau may still remain in 13A-treated neurons. To determine whether the soluble state of J3A-induced somatodendritic tau could be secondary to 13A-induced disruption of microtubules, we examined the cytoskeletal association of MAP2 in 13A-treated neurons. In contrast to tau, MAP2 was not released by detergent extraction and remained associated with the detergent-resistant cytoskeleton in the somatodendritic compartment (Figure 7) , suggesting that the microtubules are intact.
Detergent-extracted
Western blot analysis confirmed that 13A-induced phosphorylated tau is soluble. 13A-induced tau was recovered predominantly in the detergent-soluble fraction and was minimally associated with the detergent-resistant cytoskeletal fraction ( Figure 4A, arrows) . In contrast, nonphosphorylated tau detected by the Tau-1 antibody was recovered predominantly in the detergent-resistant cytoskeletal fraction, and its level was not significantly affected by treatment with fibrillar I3A (Figu re 4A), suggesting that 13A does not prevent the association of nonphosphorylated tau with microtubules. In addition, MAP2 was recov- ered predominantly in the detergent-resistant fraction, and its level was unaffected by fibrillar 13A ( Figure 4A ). These results suggest that I~A induces a phosphorylated form of tau that is not bound to microtubules. To confirm that 13A-induced tau is soluble because of a loss of microtubule binding capacity, binding assays to purified, preassembled microtubules were performed. 13A-induced phosphorylated tau was recovered from the soluble fraction of detergent-extracted cells and added to preassembled microtubules in vitro under conditions of +#A CONTROL CYTOSKELETON Figure 7 . ~A-Induced Phosphorylated Tau Is Not Bound to the Cytoskeleton Rat hippocampal neurons were incubated in the absence (-13A) or presence (+~A) of fibrillar ~A. Shown are intact neurons (CONTROL) and neurons extracted with Triton X-100 under microtubule-stabilizing conditions (CYTOSKELE-TON) as described in Experimental Procedures. Immunocytochemistry was performed with antibody PHF-1 or AP20 (to MAP2) as designated. Normal fetal tau is localized to axons and is not released by detergent extraction, indicating that it is bound to microtubules. In fibrillar I~A-treated neurons, PHF-l-immunoreactive tau is released from the somatodendritic compartment, but axonal tau remains bound (arrows). MAP2 is bound to the somatodendritic cytoskeleton of fibdllar 13A-treated neurons, indicating that microtubules are intact. Bar, 40 pm. +pA microtubule excess. The 13A-induced tau did not bind to microtubules ( Figure 4B , negative [-] lanes). After dephosphorylation with alkaline phosphatase, the ability of 13A-induced tau to bind to microtubules was restored, as determined by its recovery in the microtubule-containing pellet ( Figure 4B , positive [+] lanes). Microtubule-bound tau lost its immunoreactivity with PHF-1 and became immunoreactive with the Tau-1 antibody, confirming that it was dephosphorylated. These results indicate that tau phosphorylation induced by fibrillar 13A results in the loss of microtubule binding capacity.
Discussion
These experiments demonstrate that the ~A fibril induces tau phosphorylation. Exposure of primary rat and human neurons to fibrillar ~A resulted in increased absolute and relative levels of tau phosphorylated at Ser-202 and Ser-396/Ser-404. Previous studies have shown that 13A neurotoxicity is accompanied by the induction of immunoreactivity for the AIz-50 antibody (Kowall et al., 1991 ; Takashima et a1.,1993; Snow et al., 1994) . Although AIz-50 recognizes a tau epitope associated with PHFs in the AD brain (WoIozin et al., 1986) , this antibody is not specific for phosphorylated derivatives of tau (Ksiezak-Reding et al., 1990; Goedert et al., 1991) . In contrast, the PHF-1 and AT8 monoclonal antibodies used in this study are specific for phosphorylation-dependent tau epitopes present in fetal brain and in PHFs (Biernat et al., 1992; Greenberg et al., 1992; Bramblett et al., 1993; Goedert et al., 1993) . Normal fetal tau and PHF-tau in the AD brain are phosphorylated at common sites (Kanemaru et al., 1992; Kenessey and Yen, 1993) , but PHF-tau is distinguished by the extent of phosphorylation and the phosphorylation of additional sites, which may account for its altered properties (Hasegawa et al., 1992; Biernat et al., 1993; Matsuo et al., 1994) . We observed several differences between tau in normal fetal neurons and in neurons treated with fibrillar 13A. First, fibrillar 13A increased the level of phosphorylated tau and, in human cortical neurons, caused a shift to higher Mr forms of phosphorylated tau. The higher Mr phosphorylated forms normally represent only a small fraction of the phosphorylated tau in fetal human cortical neurons, but after exposure to fibrillar I~A, the higher M, forms become the predominant phosphorylated tau species. Thus, fibrillar 13A causes hyperphosphorylation of tau in human cortical neurons. Second, fibrillar 13A markedly increased the accumulation of phosphorylated tau in the somatodendritic compartment. Similarly, in the AD brain the normal axonal localization of tau (Binder et al., 1985; Kosik et al., 1988) is altered with the appearance of tau in the somatodendritic compartment (Kowall and Kosik, 1987; Ihara, 1988; McKee et al., 1989; Delacourte et al., 1990) . Third, 13A-induc.ed tau appears to be incapable of binding to microtubules. These properties of ~A-induced tau are similar to those exhibited by PHF-tau in AD. However, immunocytochemical analysis of 13A-treated cultures did not provide evidence of neurofibrillary tangle formation. The development of PHFs leading to neurofibrillary tangle formation may require additional age-related factors not present in fetal cultures. PHF-tau does not bind to microtubules or effectively pro-mote microtubule assembly, whereas fetal phosphorylated tau binds to microtubules and promotes microtubule assembly Biernat et al., 1993; Lu and Wood, 1993; Yoshida and Ihara, 1993; Alonso et al., 1994) . We have observed a similar dichotomy for I~A-induced phosphorylated tau and fetal phosphorylated tau. The phosphorylated tau induced by fibrillar I~A is not bound to microtubules in whole-cell preparations and does not bind to isolated microtubules in vitro. In contrast, the phosphorylated tau in untreated fetal neurons is not released by detergent extraction, suggesting that it may be bound to microtubules in the axonal cytoskeleton. Interestingly, detergent extraction of I~A-treated neurons selectively released the induced tau in the somatodendritic compartment but not in axons, suggesting that the latter may be normal fetal tau. Thus, normal fetal phosphorylated tau appears to be mostly bound to microtubules, whereas 13A-induced tau is not associated with microtubules. In this respect, 13A-induced tau is more similar to PHF-tau than to normal fetal phosphorylated tau. The ability of I~A-induced tau to bind to m icrotubules was restored by dephosphorylation, indicating that ~A-induced phosphorylation is responsible for the inhibition of microtubule binding. However, it is unclear whether the phosphorylation sites recognized by the PHF-1 and AT8 antibodies are solely responsible for the absence of microtubule binding. Phosphorylation of Ser-396, the PHF-l-immunoreactive epitope, is present in both normal fetal tau and 13A-induced tau, yet the two differ in cellular distribution and cytoskeletal association. This difference may be due to I~A-induced phosphorylation of other sites that are not phosphorylated in normal fetal tau, such as Ser-262 (Hasegawa et al., 1992; Biernat et al., 1993) . The resultant loss of microtubule binding capacity may prevent the transport of tau into the axon, causing accumulation of tau in the somatodendritic compartment. Loss of microtubule binding may also contribute to the neurotoxicity of fibrillar 13A by destabilizing microtubules, resulting in neuritic dystrophy and impaired axonal transport. In addition to altering the properties of tau, fibrillar 13A also increased the absolute level of tau, suggesting that as neurons degenerate tau continues to accumulate, which may in turn accelerate neuronal death.
The effects of fibrillar I3A on tau phosphorylation could be the result of increased kinase or decreased phosphatase activity (Matsuo et al., 1994) . It has been shown that 13A can increase the activity of several different protein kinases that could potentially phosphorylate tau, including protein kinase C (Chauhan et al., 1991) , casein kinases I and II (Chauhan et al., 1993) , and tau protein kinase I (Takashima et al., 1993) . It has also been reported that 13A neurotoxicity can be prevented by inhibiting the synthesis of tau protein kinase I using antisense oligonucleotides (Takashima et al., 1993) . These results, and our finding that increased tau phosphorylation is an early neuronal response to fibrillar I~A, raise the possibility that altered protein kinase or phosphatase activity may play an important role in the signal transduction system that underlies hA neurotoxicity.
Our results provide a potential link between the two primary histopathological features of the AD brain, amyloid plaques and neurofibrUlary tangles. Amyloid deposits in the brain evolve from a diffuse form containing amorphous aggregated 13A and some fibrils to a compact form containing a high density of amyloid fibrils (reviewed in Yankner and Mesulam, 1991) . Diffuse amyloid appears to be inert, whereas compacted fibrillar amyloid is associated with dystrophic neurites and neurofibrillary tangles. This observation in vivo is consistent with our finding in cell culture that fibril formation is required for 13A neurotoxicity and the induction of tau phosphorylation. Increased tau phosphorylation may also induce further production of 13A, thereby increasing the rate of amyloid fibril formation in a positive feedback loop (Shin et al., 1993) . Recent studies suggest that different amyloid fibrils and amyloidogenic peptides (Forloni et al., 1993; May et al., 1993 ) possess a common cytopathic activity. We have found that amyloid fibrils composed of diabetesassociated amylin also induce tau phosphorylation at Ser-396/Ser-404, with somatodendritic accumulation similar to that in fibrillar ~A-treated neurons (A. L., J. B., and B. A. Y., unpublished data). This observation supports the hypothesis of a common amyloid fibril-mediated mechanism and raises the possibility that other amyloidoses of the brain, such as the prion-related disorders, may also induce abnormal tau phosphorylation. Neurofibrillary tangles and dystrophic neurites can appear in regions of the AD brain seemingly devoid of amyIoid deposits (reviewed in Goedert, 1993) . In addition, the onset of dementia correlates more closely with synapse loss and the number of neurofibrillary tangles than with the total amyloid plaque burden in the brain (Terry et al., 1991; Arriagada et al., 1992) . However, our results suggest that plaque formation is not necessary for 13A-induced neurotoxicity and tau hyperphosphorylation. In primary cultures of human neurons, I~A fibrils induce neurotoxicity and tau phosphorylation without evidence of plaque formation. This observation suggests that early stages of J3A fibril deposition may lead to neurofibrillary pathology in the absence of plaques. The mature plaque may therefore reflect a very late stage of 13A fibril accumulation that is evident histologically only after considerable neuronal damage has already occurred. It is also possible that I~A causes neurofibrillary pathological changes in the immediate vicinity of plaques but is not the cause of neurofibrillary pathology in other plaque-free regions of the AD brain. It remains to be determined whether amyloidosis is the primary cause of neurofibrillary pathology in the AD brain or one of several neuronal insults that together result in dementing illness.
Experimental Procedures
Cell Culture Primary rat hippocampal cultures were established from embryonic day 18 fetuses as described previously at 1 x 106 cells per 60 mm plate on polylysine-coated glass coverslips. Primary human cortical cultures were established from 15-17 weekgestation human fetal abortuses as described previously (Busciglio et al., 1993b) . The protocol for tissue procurement complied with federal and institutional guidelines for fetal research. Rat and human primary cultures were plated in DMEM with 10% supplemented calf serum (HyCIone). After 24 hr, the medium was changed to serum-free DMEM with N2 supplements (GIBCO). A 30°/0 change of medium was performed every 3 days.
Peptides and Treatments
Synthetic 13A peptides were obtained from Bachem (lots ZL600, ZL243, and ZL573) and from Sigma (lot 93H4950). The 1-40 I3A peptide was dissolved in double-distilled H=O to 3 mg/ml, further diluted in PBS to 1.5 mg/ml, and used immediately (soluble form) or after preincubation at 37°C for 2-5 days to preaggregate the peptide. The predominant aggregated form of 1-40 I~A in this preparation is the amyloid fibril, as determined by electron microscopy and Congo red birefringence . Soluble or fibrillar I~A was added directly to culture medium to a final concentration of 20 pM; control cultures received the same volume of PBS vehicle. Peptides were added to rat hippocampal cultures 4 days after plating and incubated for 4 days. Peptides were added to high density human cortical cultures after 35 days in culture and incubated for 14 days as described previously (Busciglio et al., 1993b) . In some experiments, fibrillar and amorphous aggregates of 1-42 ~A were generated as described and added to cultures.
Immunocytochemistry
The following primary antibodies were used in this study: a monoclonal antibody to MAP2 (clone AP20; 1:500; Sigma), a monoclonal antibody to dephosphorylated epitopes of tau at Ser-199 and Ser-202 (Tau-1; 1:200; Boehringer Mannheim; Binder et al., 1985) , a monoclonal antibody to a phosphorylated tau epitope at Ser-202 (AT8; 30 i~g/ml; Biernat et al., 1992), a monoclonal antibody to phosphorylated tau epitopes at Ser-396 and Ser-404 (PHF-1; 1:1000; Greenberg et al., 1992) , and a monoclonal antibody to a-tubulin (clone DM1A; 1:2000; Sigma). Cultures were fixed in 4% paraformaldehyde, 0.12 M sucrose in PBS for 30 min and permeabilized with 0.2% Triton X-100. For immunocytochemistry, fixed cells were incubated with primary antibody for 12 hr at 4°C. The cells were then incubated with biotinylated anti-mouse IgG (1:200) for 1 hr at 20°C, followed by ExtrAvidin-peroxidase (1: 200) and diaminobenzidine. For immunofluorescence, rhodamine-or fluorescein-conju gated anti-mouse IgG secondary antibodies (1:100; 1 hr at 20°C) were used. Sequential labeling for PHF-1 and MAP2 was performed by first incubating with PHF-1 and a biotin-conjugated secondary antibody followed by Avidin-Texas red, and then incubating with anti-MAP2 and a fluorescein-conjugated secondary antibody. Dephosphorylation was performed by incubating fixed and permeabilized cells with Escherichia coil alkaline phosphatase (50 U/ml; Sigma) and bovine intestinal alkaline phosphatase (50 U/ml; Boehringer Mannhelm) in 50 mM Tris-HCI (pH 8.0), 0.1 mM EGTA, and the protease inhibitors phenylmethylsulfonyl fluoride (1 mg/ml), aprotinin (10 I~g/ ml), leupeptin (20 mg/ml), and pepstatin (20 ~g/ml) for 12 hr at 37°C.
Neuronal Counts
To assess cell viability, living cultures were incubated with 5 p_g/ml propidium iodide for 10 min, washed with PBS, and then fixed and processed for immunocytochemistry. Viable neurons exclude propidium iodide. Scoring of viable neurons was performed in 14-20 microscopic fields (0.4 mm 2 per field) per culture in duplicate cultures using bright-field illumination to detect PHF-l-peroxidase staining and epifluorescence to detect propidium iodide uptake. More than 380 neurons were scored in control cultures.
Preparation of Cytoskeletal Fractions
Preparation of the detergent-resistant cytoskeleton from neurons in culture was performed as described (Caceres et al., 1986) . Living cultures were washed with prewarmed microtubule-stabilizing buffer (0.13 M HEPES [pH 6.9], 2 mM MgCI2, 10 rnM EGTA) and then extracted in the same buffer with 0.2% Triton X-100 for 2 rain at 37°C. For immunocytochemistry, the cultures were fixed and staining was performed on the Triton-resistant neuronal cytoskeleton remaining on the coverslip. For Western blot analysis, cultures grown in 60 mm culture dishes were extracted with 2 ml of 0.2% Triton X-100/microtubule stabilizing buffer, and the insoluble cytoskeletal fraction on the coverslip was harvested in SDS-reducing sample buffer and boiled.
The Triton-soluble fraction was clarified by centrifugation at 100,000 x g for 30 min.
Western Blot Analysis
Cultures were washed with PBS, suspended in SDS-reducing sample buffer using a cell scraper, and boiled for 5 rain. The extract was clarified by centrifugation at 100,000 x g for 30 min. The supernatants were collected, and the protein content was determined by the Bio-Rad protein assay. Protein (20 ixg per lane) was loaded in 4%-20% gradient SDS-polyacrylamide gels and electrotransferred to nitrocellulose. The blots were blocked in 5% nonfat dry milk, incubated with primary antibody for 12 hr at 4°C, and then incubated with a peroxidase-conju gated secondary antibody (1:1000; Amersham) for 1 hr. Immunodetection was performed by enhanced chemiluminescence (Amersham). For dephosphorylation, the nitrocellulose blots were treated with 25 U/ml E. coil alkaline phosphatase in 50 mM Tris-HCI [pH 8.0], 0.1 mM EDTA and the protease inhibitors described above for 1 hr at 67°C, followed by incubation with primary antibody.
Immunoprecipitation
The Triton-soluble fraction of cytoskeletal preparations was incubated with the Tau-1 (1:200) or PHF-1 (1:500) antibody in the presence of the protease inhibitors described above for 4 hr at 4°C and then immunoprecipitated with protein A-Sepharose (Pharmacia). The protein A-Sepharose was washed with PBS, resuspended in SDSreducing sample buffer, boiled, and resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then electrotransferred to nitrocellulose for Western blotting.
Microtubule Binding Assay
Tubulin was isolated by phosphocellulose chromatography from twice-cycled bovine brain microtubules as described (Williams and Dietrich, 1979; Murthy and Flavin, 1983) . Purified tubulin was then assembled into microtubules by incubation in assembly buffer (0.1 M MES [pH 6.8], 0.5 mM MgSO4, 1 mM EGTA, 2 mM dithiothreitol, 2 mM GTP, 20 IxM taxoi) for 30 min at 37°C (Vallee, 1982; Bramblett et al., 1993) . Preassembled microtubules (1 mg/ml)were then incubated at 37°C for 30 min with phosphorylated or dephosphorylated Triton-soluble fractions from cytoskeletal extractions of J~A-treated cultures. The molar ratio of tubulin:tau was >50:1 as determined by the concentration of heat-stable tau. Microtubules were centrifuged at 50,000 x g for 30 min, and the pellet was washed by additional centrifugation at 50,000 x g in assembly buffer/10% sucrose. Microtubules were resuspended in SDS-reducing sample buffer, resolved by SDS-PAGE, and electrotransferred to nitrocellulose for Western blotting with antibody PHF-1 or Tau-1. To dephosphorylate I~A-induced tau, the Triton-soluble cell extract was adjusted to pH 8.0 with NaOH and incubated with 25 U/ml E. coil alkaline phosphatase (Sigma) in the presence of the protease inhibitors described above for I hr at 67°C. The pH was then adjusted to 6.8 for the microtubule binding assay.
